ID

23355

Beschreibung

Comparison of Exenatide Taken Before Lunch and Dinner With Before Breakfast and Dinner in Patients With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT00359879

Link

https://clinicaltrials.gov/show/NCT00359879

Stichworte

Versionen (1)
  1. 03.07.17 03.07.17 -
Hochgeladen am

3. Juli 2017

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Type 2 Diabetes NCT00359879

Englisch

Eligibility Type 2 Diabetes NCT00359879

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
diagnosed with type 2 diabetes.
Beschreibung

Diabetes Mellitus, Non-Insulin-Dependent

Datentyp

boolean

Alias
UMLS CUI [1]
C0011860
have been treated with one of the following treatment regimens for at least three months prior to screening: *metformin alone; *sulfonylurea (su) alone;
Beschreibung

Metformin | Sulfonylurea

Datentyp

boolean

Alias
UMLS CUI [1]
C0025598
UMLS CUI [2]
C0038766
*thiazolidinedione (tzd) alone; *a combination of metformin and su; *a combination of metformin and tzd.
Beschreibung

Thiazolidinediones | Metformin | Sulfonylurea

Datentyp

boolean

Alias
UMLS CUI [1]
C1257987
UMLS CUI [2]
C0025598
UMLS CUI [3]
C0038766
hba1c between 7.1% and 10.0%, inclusive.
Beschreibung

Glycosylated hemoglobin A

Datentyp

boolean

Alias
UMLS CUI [1]
C0019018
body mass index (bmi) > 25 kg/m^2 and < 45 kg/m^2
Beschreibung

Body mass index

Datentyp

boolean

Alias
UMLS CUI [1]
C1305855
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
have participated in an interventional, medical, surgical, or pharmaceutical study (a study in which an experimental drug, medical, or surgical treatment was given) within 30 days prior to screening.
Beschreibung

Study Subject Participation Status | Interventional procedure | Therapeutic procedure | Operative Surgical Procedures | Investigational New Drugs

Datentyp

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0184661
UMLS CUI [3]
C0087111
UMLS CUI [4]
C0543467
UMLS CUI [5]
C0013230
have characteristics contraindicating metformin, su, or tzd use.
Beschreibung

Medical contraindication Metformin | Medical contraindication Sulfonylurea | Medical contraindication Thiazolidinediones

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1301624
UMLS CUI [1,2]
C0025598
UMLS CUI [2,1]
C1301624
UMLS CUI [2,2]
C0038766
UMLS CUI [3,1]
C1301624
UMLS CUI [3,2]
C1257987
are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical and inhaled preparations) or have received such therapy within 2 weeks immediately prior to screening.
Beschreibung

Glucocorticoid therapy systemic chronic | Topical glucocorticoid | Glucocorticoids Inhalation

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0744425
UMLS CUI [1,2]
C0205373
UMLS CUI [1,3]
C0205191
UMLS CUI [2]
C0017712
UMLS CUI [3,1]
C0017710
UMLS CUI [3,2]
C0205535
have used any prescription drug to promote weight loss within 3 months prior to screening.
Beschreibung

Weight-Loss Agents

Datentyp

boolean

Alias
UMLS CUI [1]
C0376606
are currently treated (for greater than 2 consecutive weeks) with any of the following excluded medications: *insulin within 3 months prior to screening;
Beschreibung

Insulin

Datentyp

boolean

Alias
UMLS CUI [1]
C0021641
*alpha-glucosidase inhibitors within 3 months prior to screening; *meglitinides within 3 months prior to screening; *drugs that directly affect gastrointestinal motility
Beschreibung

alpha-Glucosidase Inhibitors | Meglitinide | Pharmaceutical Preparations Affecting Gastrointestinal Motility

Datentyp

boolean

Alias
UMLS CUI [1]
C1299007
UMLS CUI [2]
C0065880
UMLS CUI [3,1]
C0013227
UMLS CUI [3,2]
C0392760
UMLS CUI [3,3]
C0017184
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Type 2 Diabetes NCT00359879

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Diabetes Mellitus, Non-Insulin-Dependent
Item
diagnosed with type 2 diabetes.
boolean
C0011860 (UMLS CUI [1])
Metformin | Sulfonylurea
Item
have been treated with one of the following treatment regimens for at least three months prior to screening: *metformin alone; *sulfonylurea (su) alone;
boolean
C0025598 (UMLS CUI [1])
C0038766 (UMLS CUI [2])
Thiazolidinediones | Metformin | Sulfonylurea
Item
*thiazolidinedione (tzd) alone; *a combination of metformin and su; *a combination of metformin and tzd.
boolean
C1257987 (UMLS CUI [1])
C0025598 (UMLS CUI [2])
C0038766 (UMLS CUI [3])
Glycosylated hemoglobin A
Item
hba1c between 7.1% and 10.0%, inclusive.
boolean
C0019018 (UMLS CUI [1])
Body mass index
Item
body mass index (bmi) > 25 kg/m^2 and < 45 kg/m^2
boolean
C1305855 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Study Subject Participation Status | Interventional procedure | Therapeutic procedure | Operative Surgical Procedures | Investigational New Drugs
Item
have participated in an interventional, medical, surgical, or pharmaceutical study (a study in which an experimental drug, medical, or surgical treatment was given) within 30 days prior to screening.
boolean
C2348568 (UMLS CUI [1])
C0184661 (UMLS CUI [2])
C0087111 (UMLS CUI [3])
C0543467 (UMLS CUI [4])
C0013230 (UMLS CUI [5])
Medical contraindication Metformin | Medical contraindication Sulfonylurea | Medical contraindication Thiazolidinediones
Item
have characteristics contraindicating metformin, su, or tzd use.
boolean
C1301624 (UMLS CUI [1,1])
C0025598 (UMLS CUI [1,2])
C1301624 (UMLS CUI [2,1])
C0038766 (UMLS CUI [2,2])
C1301624 (UMLS CUI [3,1])
C1257987 (UMLS CUI [3,2])
Glucocorticoid therapy systemic chronic | Topical glucocorticoid | Glucocorticoids Inhalation
Item
are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical and inhaled preparations) or have received such therapy within 2 weeks immediately prior to screening.
boolean
C0744425 (UMLS CUI [1,1])
C0205373 (UMLS CUI [1,2])
C0205191 (UMLS CUI [1,3])
C0017712 (UMLS CUI [2])
C0017710 (UMLS CUI [3,1])
C0205535 (UMLS CUI [3,2])
Weight-Loss Agents
Item
have used any prescription drug to promote weight loss within 3 months prior to screening.
boolean
C0376606 (UMLS CUI [1])
Insulin
Item
are currently treated (for greater than 2 consecutive weeks) with any of the following excluded medications: *insulin within 3 months prior to screening;
boolean
C0021641 (UMLS CUI [1])
alpha-Glucosidase Inhibitors | Meglitinide | Pharmaceutical Preparations Affecting Gastrointestinal Motility
Item
*alpha-glucosidase inhibitors within 3 months prior to screening; *meglitinides within 3 months prior to screening; *drugs that directly affect gastrointestinal motility
boolean
C1299007 (UMLS CUI [1])
C0065880 (UMLS CUI [2])
C0013227 (UMLS CUI [3,1])
C0392760 (UMLS CUI [3,2])
C0017184 (UMLS CUI [3,3])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video